In September, at the World Cardiology Congress in Barcelona,Donald Baim, a cardiologist who is the new chief medical andscientific officer of Boston Scientific, was talking to a reporterwhen he mentioned disturbing new findings regarding the riskof late thrombosis associated with drug-eluting coronary stents.The revelation fueled a newly ignited controversy. Lauded asa means of preventing restenosis, drug-eluting stents have beenimplanted in nearly 6 million patients worldwide since theywere introduced 3 years ago. The Food and Drug Administration(FDA) responded to the controversy by issuing a statement thatdrug-eluting stents are "safe and effective . . . [Full Text of this Article]
Source Information
Dr. Shuchman is an assistant professor in the Department of Psychiatry at the University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY.
This article has been cited by other articles:
Aldea, G. S., Mokadam, N. A., Melford, R. Jr, Stewart, D., Maynard, C., Reisman, M., Goss, R.
(2009). Changing Volumes, Risk Profiles, and Outcomes of Coronary Artery Bypass Grafting and Percutaneous Coronary Interventions.. Ann. Thorac. Surg.
87: 1828-1838
[Abstract][Full Text]
Brar, S. S., Leon, M. B., Stone, G. W., Mehran, R., Moses, J. W., Brar, S. K., Dangas, G.
(2009). Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis.. J Am Coll Cardiol
53: 1677-1689
[Abstract][Full Text]
Nakano, K., Egashira, K., Masuda, S., Funakoshi, K., Zhao, G., Kimura, S., Matoba, T., Sueishi, K., Endo, Y., Kawashima, Y., Hara, K., Tsujimoto, H., Tominaga, R., Sunagawa, K.
(2009). Formulation of Nanoparticle-Eluting Stents by a Cationic Electrodeposition Coating Technology: Efficient Nano-Drug Delivery via Bioabsorbable Polymeric Nanoparticle-Eluting Stents in Porcine Coronary Arteries. J Am Coll Cardiol Intv
2: 277-283
[Abstract][Full Text]
Wong, B. Y.L., Kim, D. H., Rothman, K. J., Mauri, L., Normand, S.-L. T.
(2009). Drug-eluting versus bare-metal stents in acute myocardial infarction.. NEJM
360: 300-301
[Full Text]
Park, D.-W., Yun, S.-C., Lee, S.-W., Kim, Y.-H., Lee, C. W., Hong, M.-K., Cheong, S.-S., Kim, J.-J., Park, S.-W., Park, S.-J.
(2008). Stent Thrombosis, Clinical Events, and Influence of Prolonged Clopidogrel Use After Placement of Drug-Eluting Stent: Data From an Observational Cohort Study of Drug-Eluting Versus Bare-Metal Stents. J Am Coll Cardiol Intv
1: 494-503
[Abstract][Full Text]
Malenka, D. J., Kaplan, A. V., Lucas, F. L., Sharp, S. M., Skinner, J. S.
(2008). Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents. JAMA
299: 2868-2876
[Abstract][Full Text]
Kelbaek, H., Klovgaard, L., Helqvist, S., Lassen, J. F., Krusell, L. R., Engstrom, T., Botker, H. E., Jorgensen, E., Saunamaki, K., Aljabbari, S., Thayssen, P., Galloe, A., Jensen, G. V.H., Thuesen, L.
(2008). Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions: 3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) Trial. J Am Coll Cardiol
51: 2011-2016
[Abstract][Full Text]
Hannan, E. L., Racz, M., Holmes, D. R., Walford, G., Sharma, S., Katz, S., Jones, R. H., King, S. B. III
(2008). Comparison of Coronary Artery Stenting Outcomes in the Eras Before and After the Introduction of Drug-Eluting Stents. Circulation
117: 2071-2078
[Abstract][Full Text]
Hannan, E. L., Racz, M., Walford, G., Holmes, D. R., Jones, R. H., Sharma, S., Katz, S., King, S. B. III
(2008). Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol Intv
1: 129-135
[Abstract][Full Text]
Tu, J. V., Bowen, J., Chiu, M., Ko, D. T., Austin, P. C., He, Y., Hopkins, R., Tarride, J.-E., Blackhouse, G., Lazzam, C., Cohen, E. A., Goeree, R.
(2007). Effectiveness and Safety of Drug-Eluting Stents in Ontario. NEJM
357: 1393-1402
[Abstract][Full Text]
Schomig, A., Dibra, A., Windecker, S., Mehilli, J., Suarez de Lezo, J., Kaiser, C., Park, S.-J., Goy, J.-J., Lee, J.-H., Di Lorenzo, E., Wu, J., Juni, P., Pfisterer, M. E., Meier, B., Kastrati, A.
(2007). A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. J Am Coll Cardiol
50: 1373-1380
[Abstract][Full Text]
Daemen, J., Serruys, P. W.
(2007). Drug-Eluting Stent Update 2007: Part II: Unsettled Issues. Circulation
116: 961-968
[Full Text]
Bode, C., Zehender, M.
(2007). The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis. Eur Heart J Suppl
9: D10-D19
[Abstract][Full Text]
Howard-Alpe, G. M., de Bono, J., Hudsmith, L., Orr, W. P., Foex, P., Sear, J. W.
(2007). Coronary artery stents and non-cardiac surgery. Br J Anaesth
98: 560-574
[Abstract][Full Text]
Kastrati, A., Mehilli, J., Pache, J., Kaiser, C., Valgimigli, M., Kelbaek, H., Menichelli, M., Sabate, M., Suttorp, M. J., Baumgart, D., Seyfarth, M., Pfisterer, M. E., Schomig, A.
(2007). Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. NEJM
356: 1030-1039
[Abstract][Full Text]
Rocca, H.-P. B.-L., Kaiser, C., Pfisterer, M., on behalf of the BASKET Investigators,
(2007). Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET). Eur Heart J
28: 719-725
[Abstract][Full Text]
Lang, N. N., Newby, D. E.
(2007). Emerging Thrombotic Effects of Drug Eluting Stents. Arterioscler. Thromb. Vasc. Bio.
27: 261-262
[Full Text]
Shuchman, M.
(2007). Debating the Risks of Drug-Eluting Stents. NEJM
356: 325-328
[Full Text]
Knudtson, M. L.
(2007). Drug-eluting coronary stents: faith and hope, but no charity. CMAJ
176: 195-196
[Full Text]
